The Pharma Letter10h
Merck's Keytruda and Citius' Lymphir combo trial shows promising results
Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...
Aethlon Medical enrols first patient in trial of Hemopurifier device for cancer
"Aethlon Medical enrols first patient in trial of Hemopurifier device for cancer " was originally created and published by ...
Business Insider14h
Medicenna announces single-agent activity of MDNA11 from dose expansion cohort
The Safety Review Committee approved enrollment of the next higher-dose cohorts as follows: Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 mg Q6W KEYTRUDA; Cohort 4: 120 microgram/kg Q3W MDNA11 and 400 ...
Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in Australia
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first ...
manilatimes18h
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company's most advanced ...
Aethlon Medical, Inc.: Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier Cancer Trial in Australia
Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® ...